{"id":"https://openalex.org/W7225640738","doi":"https://doi.org/10.5414/cp205039","title":"CD14 monocyte PD-L1 and VEGF-A reductions are associated with improved survival after sintilimab plus DOX in advanced gastric cancer","display_name":"CD14 monocyte PD-L1 and VEGF-A reductions are associated with improved survival after sintilimab plus DOX in advanced gastric cancer","publication_year":2026,"publication_date":"2026-11-09","ids":{"openalex":"https://openalex.org/W7225640738","doi":"https://doi.org/10.5414/cp205039","pmid":"https://pubmed.ncbi.nlm.nih.gov/43001356"},"language":"en","primary_location":{"id":"doi:10.5414/cp205039","doi":"https://doi.org/10.5414/cp205039","is_oa":false,"landing_page_url":"https://doi.org/10.5414/cp205039","pdf_url":null,"source":{"id":"https://openalex.org/S166536441","display_name":"International Journal of Clinical Pharmacology and Therapeutics","issn_l":"0946-1965","issn":["0946-1965"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","medline","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310313675","host_organization_name":"Dustri-Verlag","host_organization_lineage":["https://openalex.org/P4310313675"],"host_organization_lineage_names":["Dustri-Verlag"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Int. Journal of Clinical Pharmacology and Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5161329227","display_name":"Dongdong Wang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dongdong Wang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5061393446","display_name":"Guozhi Zhou","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Guozhi Zhou","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.7411999702453613,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.7411999702453613,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.25270000100135803,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12064","display_name":"Intraperitoneal and Appendiceal Malignancies","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/advanced-gastric-cancer","display_name":"advanced gastric cancer","score":0.8939999938011169},{"id":"https://openalex.org/keywords/sintilimab","display_name":"sintilimab","score":0.9980000257492065},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":0.8270000219345093},{"id":"https://openalex.org/keywords/oxaliplatin","display_name":"oxaliplatin","score":0.8389999866485596},{"id":"https://openalex.org/keywords/capecitabine","display_name":"capecitabine","score":0.9980000257492065},{"id":"https://openalex.org/keywords/pd-l1","display_name":"PD-L1","score":0.6600000262260437},{"id":"https://openalex.org/keywords/vegf-a","display_name":"VEGF-A","score":0.8650000095367432},{"id":"https://openalex.org/keywords/cd14-monocytes","display_name":"CD14+ monocytes","score":0.9100000262260437},{"id":"https://openalex.org/keywords/angiogenic-biomarkers","display_name":"angiogenic biomarkers","score":0.7350000143051147},{"id":"https://openalex.org/keywords/immune-inflammatory-biomarkers","display_name":"immune-inflammatory biomarkers","score":0.9070000052452087},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.7200000286102295},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.7540000081062317},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9760000109672546}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8733000159263611},{"id":"https://openalex.org/C2777909004","wikidata":"https://www.wikidata.org/wiki/Q420207","display_name":"Capecitabine","level":4,"score":0.7376999855041504},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6572999954223633},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.6255000233650208},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6176000237464905},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6068999767303467},{"id":"https://openalex.org/C2778513237","wikidata":"https://www.wikidata.org/wiki/Q419553","display_name":"CD14","level":3,"score":0.5595999956130981},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.546999990940094},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5267999768257141},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5145999789237976},{"id":"https://openalex.org/C2781184567","wikidata":"https://www.wikidata.org/wiki/Q107244","display_name":"Monocyte","level":2,"score":0.508400022983551},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.46650001406669617},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4194999933242798},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.41690000891685486},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.32850000262260437},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.28369998931884766},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.27309998869895935},{"id":"https://openalex.org/C201903717","wikidata":"https://www.wikidata.org/wiki/Q1778788","display_name":"Cohort study","level":2,"score":0.2689000070095062},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2678999900817871},{"id":"https://openalex.org/C137061746","wikidata":"https://www.wikidata.org/wiki/Q736033","display_name":"Peripheral blood mononuclear cell","level":3,"score":0.25949999690055847},{"id":"https://openalex.org/C2776283816","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Survival rate","level":2,"score":0.25529998540878296}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.5414/cp205039","doi":"https://doi.org/10.5414/cp205039","is_oa":false,"landing_page_url":"https://doi.org/10.5414/cp205039","pdf_url":null,"source":{"id":"https://openalex.org/S166536441","display_name":"International Journal of Clinical Pharmacology and Therapeutics","issn_l":"0946-1965","issn":["0946-1965"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","medline","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310313675","host_organization_name":"Dustri-Verlag","host_organization_lineage":["https://openalex.org/P4310313675"],"host_organization_lineage_names":["Dustri-Verlag"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Int. Journal of Clinical Pharmacology and Therapeutics","raw_type":"journal-article"},{"id":"pmid:43001356","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/43001356","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International journal of clinical pharmacology and therapeutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9922999739646912,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4415935242","https://openalex.org/W7118607171","https://openalex.org/W4318483031","https://openalex.org/W4387115621","https://openalex.org/W7213473212","https://openalex.org/W7166723348","https://openalex.org/W4281650678","https://openalex.org/W4286296853","https://openalex.org/W4400126741","https://openalex.org/W7127443015"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"evaluate":[2],"the":[3],"efficacy":[4],"and":[5,12,20,26,54,91,111,120,128,152],"safety":[6],"of":[7],"sintilimab":[8,63],"plus":[9,64],"docetaxel,":[10],"oxaliplatin,":[11],"capecitabine":[13],"(DOX)":[14],"chemotherapy":[15],"in":[16,70],"advanced":[17,47],"gastric":[18,48],"cancer":[19,49],"explore":[21],"whether":[22],"dynamic":[23],"peripheral":[24],"immune-inflammatory":[25,87],"angiogenesis-related":[27,89],"biomarker":[28,98,132],"changes":[29,99],"were":[30,95,100,114,122,144],"associated":[31,124],"with":[32,46,67,125],"survival":[33,76,79,156],"benefit.":[34,157],"MATERIALS":[35],"AND":[36],"METHODS:":[37],"This":[38],"single-center":[39],"retrospective":[40],"cohort":[41],"study":[42],"included":[43],"80":[44],"patients":[45,69],"treated":[50],"between":[51,146],"June":[52,55],"2021":[53],"2022.":[56],"Patients":[57],"received":[58],"either":[59],"DOX":[60,65],"alone":[61],"or":[62],"chemotherapy,":[66],"40":[68],"each":[71],"group.":[72],"Tumor":[73],"response,":[74],"progression-free":[75],"(PFS),":[77],"overall":[78],"(OS),":[80],"36-month":[81,139],"OS":[82],"rate,":[83],"serum":[84],"tumor":[85],"markers,":[86],"indicators,":[88],"biomarkers,":[90],"treatment-related":[92],"adverse":[93],"events":[94],"compared.":[96],"Dynamic":[97],"defined":[101],"as":[102],"post-treatment":[103],"values":[104],"minus":[105],"baseline":[106],"values.":[107],"Adjusted":[108],"Cox":[109],"regression":[110],"ROC":[112],"analyses":[113],"performed.":[115],"RESULTS:":[116],"monocyte":[117,149],"PD-L1":[118,150],"expression":[119,151],"VEGF-A":[121,153],"independently":[123],"improved":[126],"PFS":[127],"OS.":[129,140],"The":[130],"combined":[131],"model":[133],"showed":[134],"moderate":[135],"performance":[136],"for":[137],"predicting":[138],"Adverse":[141],"event":[142],"rates":[143],"comparable":[145],"groups.":[147],"CONCLUSION:":[148],"may":[154],"indicate":[155]},"counts_by_year":[],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2026-11-10T00:00:00"}